Compare ALEC & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALEC | OXSQ |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.8M | 137.9M |
| IPO Year | 2019 | 2003 |
| Metric | ALEC | OXSQ |
|---|---|---|
| Price | $1.93 | $1.26 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.83 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 22.83% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | ★ $21,045,000.00 | N/A |
| Revenue This Year | $2.03 | $3.61 |
| Revenue Next Year | $29.87 | N/A |
| P/E Ratio | ★ N/A | $12.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $1.05 |
| 52 Week High | $3.40 | $2.05 |
| Indicator | ALEC | OXSQ |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 30.92 |
| Support Level | $1.43 | $1.24 |
| Resistance Level | $2.10 | $1.96 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 13.92 | 22.22 |
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.